Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

Lucilla Parnetti, Davide Chiasserini, Gianni Bellomo, David Giannandrea, Claudia de Carlo, Mohamed M. Qureshi, Mustafa T. Ardah, Shiji Varghese, Laura Bonanni, Barbara Borroni, Nicola Tambasco, Paolo Eusebi, Aroldo Rossi, Marco Onofrj, Alessandro Padovani, Paolo Calabresi, Omar Ali El-Agnaf

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Although alpha-synuclein is the main constituent of Lewy bodies, cerebrospinal fluid determination on its own does not seem fundamental for the diagnosis of synucleinopathies. We evaluated whether the combination of classical biomarkers, Aβ1-42, total tau, phosphorylated tau, and α-synuclein can improve discrimination of Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia. Aβ1-42, total tau, phosphorylated tau, and α-synuclein were measured in a series of patients with Parkinson's disease (n = 38), dementia with Lewy bodies (n = 32), Alzheimer's disease (n = 48), frontotemporal dementia (n = 31), and age-matched control patients with other neurological diseases (n = 32). Mean α-synuclein levels in cerebrospinal fluid were significantly lower in the pathological groups than in cognitively healthy subjects. An inverse correlation of α-synuclein with total tau (r = -0.196, P < .01) was observed. In the group of patients with Parkinson's disease, Aβ1-42, total tau, and phosphorylated tau values were similar to controls, whereas total tau/α-synuclein and phosphorylated tau/α-synuclein ratios showed the lowest values. Cerebrospinal fluid α-synuclein alone did not provide relevant information for Parkinson's disease diagnosis, showing low specificity (area under the curve, 0.662; sensitivity, 94%; specificity, 25%). Instead, a better performance was obtained with the total tau/α-syn ratio (area under the curve, 0.765; sensitivity, 89%; specificity, 61%). Combined determination of α-synuclein and classical biomarkers in cerebrospinal fluid shows differential patterns in neurodegenerative disorders. In particular, total tau/α-synuclein and phosphorylated tau/α-synuclein ratios can contribute to the discrimination of Parkinson's disease.

Original languageEnglish
Pages (from-to)1428-1435
Number of pages8
JournalMovement Disorders
Volume26
Issue number8
DOIs
Publication statusPublished - Jul 2011
Externally publishedYes

Fingerprint

Synucleins
Parkinson Disease
Cerebrospinal Fluid
Dementia
Lewy Body Disease
Frontotemporal Dementia
Alzheimer Disease
Area Under Curve
Biomarkers
Lewy Bodies
alpha-Synuclein
Body Fluids
Neurodegenerative Diseases
Healthy Volunteers

Keywords

  • Alpha-synuclein
  • Alzheimer's disease
  • Cerebrospinal fluid biomarkers
  • Dementia with Lewy bodies
  • Frontotemporal dementia
  • Parkinson's disease
  • Phosphorylated tau
  • Total tau

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., de Carlo, C., Qureshi, M. M., ... Ali El-Agnaf, O. (2011). Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Movement Disorders, 26(8), 1428-1435. https://doi.org/10.1002/mds.23670

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. / Parnetti, Lucilla; Chiasserini, Davide; Bellomo, Gianni; Giannandrea, David; de Carlo, Claudia; Qureshi, Mohamed M.; Ardah, Mustafa T.; Varghese, Shiji; Bonanni, Laura; Borroni, Barbara; Tambasco, Nicola; Eusebi, Paolo; Rossi, Aroldo; Onofrj, Marco; Padovani, Alessandro; Calabresi, Paolo; Ali El-Agnaf, Omar.

In: Movement Disorders, Vol. 26, No. 8, 07.2011, p. 1428-1435.

Research output: Contribution to journalArticle

Parnetti, L, Chiasserini, D, Bellomo, G, Giannandrea, D, de Carlo, C, Qureshi, MM, Ardah, MT, Varghese, S, Bonanni, L, Borroni, B, Tambasco, N, Eusebi, P, Rossi, A, Onofrj, M, Padovani, A, Calabresi, P & Ali El-Agnaf, O 2011, 'Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias', Movement Disorders, vol. 26, no. 8, pp. 1428-1435. https://doi.org/10.1002/mds.23670
Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, de Carlo C, Qureshi MM et al. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Movement Disorders. 2011 Jul;26(8):1428-1435. https://doi.org/10.1002/mds.23670
Parnetti, Lucilla ; Chiasserini, Davide ; Bellomo, Gianni ; Giannandrea, David ; de Carlo, Claudia ; Qureshi, Mohamed M. ; Ardah, Mustafa T. ; Varghese, Shiji ; Bonanni, Laura ; Borroni, Barbara ; Tambasco, Nicola ; Eusebi, Paolo ; Rossi, Aroldo ; Onofrj, Marco ; Padovani, Alessandro ; Calabresi, Paolo ; Ali El-Agnaf, Omar. / Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. In: Movement Disorders. 2011 ; Vol. 26, No. 8. pp. 1428-1435.
@article{d5cab83cc8944a908353a27f36becccb,
title = "Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias",
abstract = "Although alpha-synuclein is the main constituent of Lewy bodies, cerebrospinal fluid determination on its own does not seem fundamental for the diagnosis of synucleinopathies. We evaluated whether the combination of classical biomarkers, Aβ1-42, total tau, phosphorylated tau, and α-synuclein can improve discrimination of Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia. Aβ1-42, total tau, phosphorylated tau, and α-synuclein were measured in a series of patients with Parkinson's disease (n = 38), dementia with Lewy bodies (n = 32), Alzheimer's disease (n = 48), frontotemporal dementia (n = 31), and age-matched control patients with other neurological diseases (n = 32). Mean α-synuclein levels in cerebrospinal fluid were significantly lower in the pathological groups than in cognitively healthy subjects. An inverse correlation of α-synuclein with total tau (r = -0.196, P < .01) was observed. In the group of patients with Parkinson's disease, Aβ1-42, total tau, and phosphorylated tau values were similar to controls, whereas total tau/α-synuclein and phosphorylated tau/α-synuclein ratios showed the lowest values. Cerebrospinal fluid α-synuclein alone did not provide relevant information for Parkinson's disease diagnosis, showing low specificity (area under the curve, 0.662; sensitivity, 94{\%}; specificity, 25{\%}). Instead, a better performance was obtained with the total tau/α-syn ratio (area under the curve, 0.765; sensitivity, 89{\%}; specificity, 61{\%}). Combined determination of α-synuclein and classical biomarkers in cerebrospinal fluid shows differential patterns in neurodegenerative disorders. In particular, total tau/α-synuclein and phosphorylated tau/α-synuclein ratios can contribute to the discrimination of Parkinson's disease.",
keywords = "Aβ, Alpha-synuclein, Alzheimer's disease, Cerebrospinal fluid biomarkers, Dementia with Lewy bodies, Frontotemporal dementia, Parkinson's disease, Phosphorylated tau, Total tau",
author = "Lucilla Parnetti and Davide Chiasserini and Gianni Bellomo and David Giannandrea and {de Carlo}, Claudia and Qureshi, {Mohamed M.} and Ardah, {Mustafa T.} and Shiji Varghese and Laura Bonanni and Barbara Borroni and Nicola Tambasco and Paolo Eusebi and Aroldo Rossi and Marco Onofrj and Alessandro Padovani and Paolo Calabresi and {Ali El-Agnaf}, Omar",
year = "2011",
month = "7",
doi = "10.1002/mds.23670",
language = "English",
volume = "26",
pages = "1428--1435",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

AU - Parnetti, Lucilla

AU - Chiasserini, Davide

AU - Bellomo, Gianni

AU - Giannandrea, David

AU - de Carlo, Claudia

AU - Qureshi, Mohamed M.

AU - Ardah, Mustafa T.

AU - Varghese, Shiji

AU - Bonanni, Laura

AU - Borroni, Barbara

AU - Tambasco, Nicola

AU - Eusebi, Paolo

AU - Rossi, Aroldo

AU - Onofrj, Marco

AU - Padovani, Alessandro

AU - Calabresi, Paolo

AU - Ali El-Agnaf, Omar

PY - 2011/7

Y1 - 2011/7

N2 - Although alpha-synuclein is the main constituent of Lewy bodies, cerebrospinal fluid determination on its own does not seem fundamental for the diagnosis of synucleinopathies. We evaluated whether the combination of classical biomarkers, Aβ1-42, total tau, phosphorylated tau, and α-synuclein can improve discrimination of Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia. Aβ1-42, total tau, phosphorylated tau, and α-synuclein were measured in a series of patients with Parkinson's disease (n = 38), dementia with Lewy bodies (n = 32), Alzheimer's disease (n = 48), frontotemporal dementia (n = 31), and age-matched control patients with other neurological diseases (n = 32). Mean α-synuclein levels in cerebrospinal fluid were significantly lower in the pathological groups than in cognitively healthy subjects. An inverse correlation of α-synuclein with total tau (r = -0.196, P < .01) was observed. In the group of patients with Parkinson's disease, Aβ1-42, total tau, and phosphorylated tau values were similar to controls, whereas total tau/α-synuclein and phosphorylated tau/α-synuclein ratios showed the lowest values. Cerebrospinal fluid α-synuclein alone did not provide relevant information for Parkinson's disease diagnosis, showing low specificity (area under the curve, 0.662; sensitivity, 94%; specificity, 25%). Instead, a better performance was obtained with the total tau/α-syn ratio (area under the curve, 0.765; sensitivity, 89%; specificity, 61%). Combined determination of α-synuclein and classical biomarkers in cerebrospinal fluid shows differential patterns in neurodegenerative disorders. In particular, total tau/α-synuclein and phosphorylated tau/α-synuclein ratios can contribute to the discrimination of Parkinson's disease.

AB - Although alpha-synuclein is the main constituent of Lewy bodies, cerebrospinal fluid determination on its own does not seem fundamental for the diagnosis of synucleinopathies. We evaluated whether the combination of classical biomarkers, Aβ1-42, total tau, phosphorylated tau, and α-synuclein can improve discrimination of Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia. Aβ1-42, total tau, phosphorylated tau, and α-synuclein were measured in a series of patients with Parkinson's disease (n = 38), dementia with Lewy bodies (n = 32), Alzheimer's disease (n = 48), frontotemporal dementia (n = 31), and age-matched control patients with other neurological diseases (n = 32). Mean α-synuclein levels in cerebrospinal fluid were significantly lower in the pathological groups than in cognitively healthy subjects. An inverse correlation of α-synuclein with total tau (r = -0.196, P < .01) was observed. In the group of patients with Parkinson's disease, Aβ1-42, total tau, and phosphorylated tau values were similar to controls, whereas total tau/α-synuclein and phosphorylated tau/α-synuclein ratios showed the lowest values. Cerebrospinal fluid α-synuclein alone did not provide relevant information for Parkinson's disease diagnosis, showing low specificity (area under the curve, 0.662; sensitivity, 94%; specificity, 25%). Instead, a better performance was obtained with the total tau/α-syn ratio (area under the curve, 0.765; sensitivity, 89%; specificity, 61%). Combined determination of α-synuclein and classical biomarkers in cerebrospinal fluid shows differential patterns in neurodegenerative disorders. In particular, total tau/α-synuclein and phosphorylated tau/α-synuclein ratios can contribute to the discrimination of Parkinson's disease.

KW - Aβ

KW - Alpha-synuclein

KW - Alzheimer's disease

KW - Cerebrospinal fluid biomarkers

KW - Dementia with Lewy bodies

KW - Frontotemporal dementia

KW - Parkinson's disease

KW - Phosphorylated tau

KW - Total tau

UR - http://www.scopus.com/inward/record.url?scp=79960613150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960613150&partnerID=8YFLogxK

U2 - 10.1002/mds.23670

DO - 10.1002/mds.23670

M3 - Article

VL - 26

SP - 1428

EP - 1435

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 8

ER -